Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Breast Neoplasms 2Solid Tumor 1Sarcoma, Endometrial Stromal 1Pancreatitis, Chronic 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma 1Brain Neoplasms 1Adrenocortical Adenoma 1

Interventions

selurampanel 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1Injections 1Imatinib Mesylate 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma, Endometrial Stromal × Magnetic Resonance Spectroscopy × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡